UBS Reaffirms Their Hold Rating on Argenx Se (ARGX)

Here’s Why argenx SE (ARGX) Pulled Back 23% in Q4

Buy Rating Affirmed for Argenx Se on Efgartigimod Progress and Regulatory Success

Wall Street Analysts Are Bullish on Top Healthcare Picks

Analysts Offer Insights on Healthcare Companies: Moderna (MRNA), Argenx Se (ARGX) and NovoCure (NVCR)

Buy Rating Affirmed for Argenx Se on Strong Pipeline and Market Potential

Analysts Have Conflicting Sentiments on These Healthcare Companies: Argenx Se (ARGX), Iridex (IRIX) and Keros Therapeutics (KROS)

argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease

argenx Announces Annual General Meeting of Shareholders on May 7, 2024

Reaffirming Buy Rating for Argenx with New Price Objective Following Vyvgart’s Approval in Japan

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Day One Biopharmaceuticals (DAWN), BioMarin Pharmaceutical (BMRN) and Argenx Se (ARGX)

argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia

Buy Rating Affirmed for Argenx Following Competitive Drug Trial Failure and Promising Market Prospects for Vyvgart

Why Argenx's (ARGX) Stock Price Moved Up 11% on Thursday

Why Argenx's (ARGX) Stock Price Moved Up 11% on Thursday

Argenx (ARGX) Moves 11.2% Higher: Will This Strength Last?

Wells Fargo Issues a Buy Rating on Argenx Se (ARGX)

Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results

Buy Rating for Argenx Se Amid VYVGART’s Market Dominance and Revenue Growth Forecast

Reasons to Invest in argenx (ARGX)